SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 16.31 |
| Enterprise Value ($M) | -1.78 |
| Book Value ($M) | 19.06 |
| Book Value / Share | 0.53 |
| Price / Book | 0.86 |
| NCAV ($M) | 18.43 |
| NCAV / Share | 0.52 |
| Price / NCAV | 0.88 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.41 |
| Return on Assets (ROA) | -0.19 |
| Return on Equity (ROE) | -0.38 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.93 |
| Current Ratio | 3.93 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 24.98 |
| Assets | 25.60 |
| Liabilities | 6.54 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 41.09 |
| Operating Income | -8.27 |
| Net Income | -8.07 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -19.03 |
| Cash from Investing | 13.81 |
| Cash from Financing | 0.16 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Decheng Capital Management IV (Cayman), LLC | 15.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,662 | 48,971 | 3.39 | |
| 14,963 | 141,799 | 10.55 | |
| 3,140 | 66,885 | 4.69 | |
| 18,321 | 246,106 | 7.44 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ENTX – Entera Bio Ltd. | ENVB – Enveric Biosciences, Inc. |
| EPIX – ESSA Pharma Inc. | ERNA – Ernexa Therapeutics Inc. |
| ESLA – Estrella Immunopharma, Inc. |
Financial data and stock pages provided by
Fintel.io